Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology ...
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.